GlassScriptPhysician profile
Steve Junes
NPI 1174125512
$4,385.26
in general payments reported to CMS, 2019-2025
20 companies · $1,393 in 2025
The $1,393 reported for 2025 was more than what 86% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $284 · 2022: $686 · 2023: $838 · 2024: $1,185 · 2025: $1,393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,416.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,415.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,111.54 | 2021-2025 | |
| Ardelyx, INC. | $429.25 | 2022-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $426.59 | 2024-2025 | Rezdiffra, Resmetirom |
| Phathom Pharmaceuticals, INC. | $420.76 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $269.67 | 2023-2024 | Xifaxan, Trulance |
| E.R. Squibb & Sons, L.L.C. | $245.53 | 2022 | |
| Pfizer INC. | $228.80 | 2025 | |
| Celgene Corporation | $215.04 | 2021-2023 | Zeposia |
| Braintree Laboratories, INC. | $186.73 | 2021-2025 | Sutab, Suflave |
| Janssen Biotech, INC. | $151.99 | 2023-2025 | Stelara, Tremfya |
| Qol Medical, LLC | $136.37 | 2021-2024 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $123.50 | 2022-2025 | Gattex, Eohilia |
| Intercept Pharmaceuticals, INC. | $92.61 | 2021-2025 | Ocaliva |
| Gilead Sciences, INC. | $71.66 | 2024-2025 | |
| Aimmune Therapeutics, INC. | $68.62 | 2024-2025 | Zenpep |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $63.96 | 2024 | Iqirvo |
| Novo Nordisk INC | $57.53 | 2023-2025 | Wegovy |
| Nestle Healthcare Nutrition INC. | $39.31 | 2023 | |
| Evoke Pharma, INC. | $28.49 | 2023-2025 | Gimoti |
| Merck Sharp & Dohme LLC | $17.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steve Junes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.